Scholars@Duke
construction release_alert
The Scholars Team is working with OIT to resolve some issues with the Scholars search index
cancel

Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655

Clinical Trial Grant
Duke Scholars
Thomas Eldridge Stinchcombe
Principal Investigator Thomas Eldridge Stinchcombe Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Nuvalent, Inc.

Start Date

March 17, 2023

End Date

October 31, 2027
 

Administered By

Duke Cancer Institute

Awarded By

Nuvalent, Inc.

Start Date

March 17, 2023

End Date

October 31, 2027